Tweet
Published: April 13, 2021
DOI:https://doi.org/10.1016/S2666-5247(21)00082-3
Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Xiaoming Yang, Wenjie Tan, George F Gao
BBIBP-CorV and ZF2001 are two COVID-19 vaccines developed in China. BBIBP-CorV is an inactivated virus vaccine approved for conditional marketing authorisation1 and ZF2001 is a recombinant dimeric receptor-binding domain (RBD) protein vaccine currently in phase 3 clinical trials and approved for emergency use in China and Uzbekistan.2, 3 Both vaccines showed good immunogenicity in phase 1 and 2 trials.1, 3
...
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00082-3/fulltext
DOI:https://doi.org/10.1016/S2666-5247(21)00082-3
Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Xiaoming Yang, Wenjie Tan, George F Gao
BBIBP-CorV and ZF2001 are two COVID-19 vaccines developed in China. BBIBP-CorV is an inactivated virus vaccine approved for conditional marketing authorisation1 and ZF2001 is a recombinant dimeric receptor-binding domain (RBD) protein vaccine currently in phase 3 clinical trials and approved for emergency use in China and Uzbekistan.2, 3 Both vaccines showed good immunogenicity in phase 1 and 2 trials.1, 3
...
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00082-3/fulltext